Inzy stock forecast.
At the time of writing, Incyte Corp. [INCY] stock is trading at $54.34, up 1.78%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The INCY shares have gain 1.76% over the last week, with a monthly amount glided 0.76%, and seem to be holding
Weather forecasting plays a crucial role in our daily lives, helping us plan our activities and make informed decisions. But have you ever wondered how meteorologists are able to accurately predict the weather? One of the key components in ...Weather forecasts are essential tools for planning our daily activities, especially when it comes to the next 10 days. Understanding a weather 10 day forecast can help us make informed decisions about outdoor events, travel plans, or even w...The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...The consensus price target of analysts on Wall Street is $21.00, which implies an increase of 81.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15.00 and $40.00 respectively. As a result, INZY is trading at a discount of -938.96% off the target high and -289.61% off the low.
Market cap is calculated by taking a company's price per share and multiplying it by the company's total number of shares outstanding. $12.95B. -12.7%. Market Cap / Employee. The market cap of a ...Find the latest Pop Culture Group Co., Ltd (CPOP) stock quote, history, news and other vital information to help you with your stock trading and investing.Inozyme Pharma, Inc. Stock Earnings. The value each INZY share was expected to gain vs. the value that each INZY share actually gained. INZY ( INZY) reported Q3 2023 earnings per share (EPS) of -$0.29, beating estimates of -$0.32 by 7.58%. In the same quarter last year, INZY 's earnings per share (EPS) was -$0.38.
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Inozyme Pharma, Inc.'s (NASDAQ:INZY) case, it's fantastic news for ...
For Sorrento Therapeutics stock forecast for 2023, 8 predictions are offered for each month of 2023 with average Sorrento Therapeutics stock forecast of $0.76, a high forecast of $1.2, and a low forecast of $0.36. The average Sorrento Therapeutics stock forecast 2023 represents a 127.59% increase from the last price of $0.332199990749359. Target values for the price of one Incyte share for Jan 2025. The weighted average target price per Incyte share in Jan 2025 is: 59.50. In Jan, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 7.054% volatility is expected. Pessimistic target level: 56.44. Optimistic target level: 60.73.See Inozyme Pharma, Inc. (INZY) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Get The Latest BRID Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Skip to main content. S&P 500 4,594.63. DOW 36,245.50. QQQ 389.94. ... Bread Frozen Dough Market Analysis by Top Companies and Forecast 2031. See More Headlines .
60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.
You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.
Earnings for Incyte are expected to grow by 28.00% in the coming year, from $3.00 to $3.84 per share. Incyte has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 6th, 2024 based off prior year's report dates. Read More.Free cash flow. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. 154.20M. -37.63%. Get the latest Incyte Corporation (INCY) real-time ... BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics …Inozyme Pharma stock forecast report. View INZY price target, analyst ratings, upgrades & downgrades predictions, and buy or a sell data.ARQT | Complete Arcutis Biotherapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Incyte has risen higher in 16 of those 30 years over the subsequent 52-week period, corresponding to a historical accuracy of 53.33%. Is Incyte Stock Undervalued? The current Incyte [ INCY] share price is $53.39. The Score for INCY is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.
Inozyme Pharma, Inc. Common Stock (INZY) Nasdaq Listed. DATA AS OF Nov 10, 2021 10:17 AM ET. 0. Add to Watchlist. Add to Portfolio. INZY INZY HISTORICAL DATA.Incyte has risen higher in 16 of those 30 years over the subsequent 52-week period, corresponding to a historical accuracy of 53.33%. Is Incyte Stock Undervalued? The current Incyte [ INCY] share price is $53.39. The Score for INCY is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.Inozyme Pharma's earnings are forecast to decline at 9.3% per annum while its annual revenue is expected to grow at 95.9% per year. EPS is expected to grow by 5.5% per annum.Stock Price Forecast. According to 16 stock analysts, the average 12-month stock price forecast for Incyte stock is $79.25, which predicts an increase of 47.47%. The lowest target is $60 and the highest is $100. On average, analysts rate Incyte stock as a buy.Track Inozyme Pharma Inc (INZY) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Find the latest Tantech Holdings Ltd (TANH) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest China SXT Pharmaceuticals, Inc. (SXTC) stock quote, history, news and other vital information to help you with your stock trading and investing.
Inozyme Pharma's earnings are forecast to decline at 9.3% per annum while its annual revenue is expected to grow at 95.9% per year. EPS is expected to grow by 5.5% per annum.
Overview Inozyme Pharma Inc. U.S.: Nasdaq Add to WatchlistPrice Action: INZY shares are up 26.6% at $2.81 during the premarket session on the last check Thursday. Don't miss real-time alerts on your stocks - join Benzinga Pro for free!Inozyme Pharma, Inc. Common Stock (INZY) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Find the latest Cano Health, Inc. (CANO) stock quote, history, news and other vital information to help you with your stock trading and investing.Dec 1, 2023 · 16 analysts have issued twelve-month price objectives for Alibaba Group's shares. Their BABA share price targets range from $90.00 to $150.00. On average, they expect the company's share price to reach $129.20 in the next year. This suggests a possible upside of 74.6% from the stock's current price. Dec 1, 2023 · 16 analysts have issued twelve-month price objectives for Alibaba Group's shares. Their BABA share price targets range from $90.00 to $150.00. On average, they expect the company's share price to reach $129.20 in the next year. This suggests a possible upside of 74.6% from the stock's current price.
Dec 1, 2023 · Earnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.34) to ($1.35) per share. Inozyme Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 27th, 2024 based off prior year's report dates. Read More.
Get the latest Inozyme Pharma Inc (INZY) stock quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. See the company's financial results, market news, and earnings per share for the fiscal Q2 2023 ended 6/30/23.
Nov 29, 2023 · Their INZY share price targets range from $6.00 to $23.00. On average, they predict the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 289.6% from the stock's current price. View analysts price targets for INZY or view top-rated stocks among Wall Street analysts. Oct 27, 2023 · Price Prediction Incyte price predictions from 2023 to 2027. Gain insights into monthly forecasts, trends, and analyses to make informed investment decisions. Inozyme Pharma falls after updates to rare disease program. Jul. 26, 2023 10:24 AM ET Inozyme Pharma, Inc. (INZY) By: Dulan Lokuwithana, SA News Editor. mphillips007. Inozyme Pharma ( NASDAQ: INZY ...Get the latest Inozyme Pharma Inc (INZY) stock quote, historical performance, charts, and other financial information to help you make more informed trading and …A high-level overview of BigBear.ai Holdings, Inc. (BBAI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.INCY | Complete Incyte Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Earnings Date. Feb 05, 2024 - Feb 09, 2024. Forward Dividend & Yield. N/A (N/A) Ex-Dividend Date. N/A. 1y Target Est. 74.41. Fair Value is the appropriate price for the shares of a company, based ... Find the latest Incyte Corporation (INCY) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceInozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) saw a large growth in short interest in the month of November. ... Adage Capital Partners GP L.L.C. now owns 5,537,500 shares of the company’s stock valued at $23,258,000 after buying an additional 1,287,500 shares during the last quarter. 72.03% of the stock is owned by hedge funds …
Discover historical prices for INZY stock on Yahoo Finance. View daily, weekly or monthly format back to when Inozyme Pharma, Inc. stock was issued.According to our current INZY stock forecast, the value of Inozyme Pharma shares will rise by 7.27% and reach $ 3.50 per share by November 24, 2023. According to our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).Get The Latest BRID Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Skip to main content. S&P 500 4,594.63. DOW 36,245.50. QQQ 389.94. ... Bread Frozen Dough Market Analysis by Top Companies and Forecast 2031. See More Headlines .Instagram:https://instagram. best dental coverage in floridawhat are 1964 nickels worthhow to get weed out your system asapbac stock predictions Oct 26, 2023 · Price Prediction forecast forIncyte to October 27, and an in-depth analysis for the week of 22 October to 28 October. Monthly forecasts INCY for 2023 with target levels, support & resistance insights to make informed investment decisions. crypto under 1 centpm dividend history Inozyme Pharma (INZY) In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Inozyme Pharma, with a price target of $12.00 . The company’s shares ... toytoa stock Analyst Forecast According to 16 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is $79.25, which is an increase of 46.71% from the latest price.Is Inozyme Pharma Stock Undervalued? The current Inozyme Pharma share price is $3.85. The Score for INZY is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. INZY is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.